193 related articles for article (PubMed ID: 38105466)
1. Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Collins JB; Muluneh B; Profitt S
J Oncol Pharm Pract; 2024 Mar; 30(2):385-396. PubMed ID: 38105466
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.
Iurlo A; Cattaneo D; Bucelli C; Spallarossa P; Passamonti F
Curr Treat Options Oncol; 2023 Dec; 24(12):1720-1738. PubMed ID: 38047977
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
Yu L; Qin YZ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
[No Abstract] [Full Text] [Related]
4. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
Chiwata M; Itonaga H; Sato S; Hashimoto M; Fujioka M; Kasai S; Sakamoto H; Toriyama E; Nakashima J; Kamijo R; Kitanosono H; Kobayashi Y; Horai M; Taguchi M; Matsuo M; Makiyama J; Takasaki Y; Matsuo E; Horio K; Ando K; Sawayama Y; Taguchi J; Kawaguchi Y; Tsushima H; Imanishi D; Imaizumi Y; Yoshida S; Jo T; Nonaka H; Moriuchi Y; Nagai K; Yokota KI; Hata T; Miyazaki Y
Intern Med; 2021 Jul; 60(14):2207-2216. PubMed ID: 33612681
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
Malkan UY; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
[TBL] [Abstract][Full Text] [Related]
7. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
8. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
[TBL] [Abstract][Full Text] [Related]
9. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
10. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings.
Cheng F; Li Q; Cui Z; Hong M; Li W; Zhang Y
Front Oncol; 2023; 13():1146108. PubMed ID: 37091188
[TBL] [Abstract][Full Text] [Related]
11. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
[TBL] [Abstract][Full Text] [Related]
12. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
[TBL] [Abstract][Full Text] [Related]
13. Real-world Management of CML: Outcomes and Treatment Patterns.
Held N; Atallah EL
Curr Hematol Malig Rep; 2023 Oct; 18(5):167-175. PubMed ID: 37395944
[TBL] [Abstract][Full Text] [Related]
14. Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.
Szeto AH; Bucci T; Deal A; Zhu A; Ahmad M; Cass AS; Sketch MR; Kemper R; Zeidner JF; Foster MC; Muluneh B; Crona DJ
Ann Pharmacother; 2022 Jul; 56(7):753-763. PubMed ID: 34541881
[TBL] [Abstract][Full Text] [Related]
15. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Umezawa Y; Sasaki K
Int J Hematol; 2023 Jan; 117(1):24-29. PubMed ID: 36087226
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
17. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Chitanava T; Matvienko I; Shuvaev V; Voloshin S; Martynkevich I; Vlasova Y; Efremova E; Mileeva E; Pirkhalo A; Makarova T; Vlasik R; Karyagina E; Il Ina N; Medvedeva N; Dorofeeva N; Shneider T; Siordiya N; Kulemina O; Sbityakova E; Lazorko N; Alexeeva J; Motorin D; Morozova E; Lomaia E
Front Oncol; 2023; 13():1138683. PubMed ID: 37007128
[TBL] [Abstract][Full Text] [Related]
19. A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
Cantoni N; Sommavilla R; Seitz P; Kulenkampff E; Kahn S; Lambert JF; Schmidt A; Zenhaeusern R; Balabanov S
BMC Cancer; 2022 Nov; 22(1):1192. PubMed ID: 36402993
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]